Renal Cell Carcinoma

RENAL CELL CARCINOMA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer

Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Gene Mutations and Transcriptional Signatures Correlate With Response to Therapy in Advanced Renal Cell Carcinoma

A comprehensive analysis of advanced kidney cancer tumors from the IMmotion151 trial provided new insights on the tumor features that underpin responses to therapy.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Phase 1 RCC Vaccine Is Safe, But Lacks Clinical Response

RCC vaccines are predominantly being developed using autologous tumor cells, dendritic cells, genetically modified tumor cells, and peptides.

VIDEO SERIES

Tivozanib for RCC

Genitourinary Oncology: A Peek Over the Horizon

Immunotherapy of Renal Cell Carcinoma

Targeted Therapies for Renal Cell Carcinoma

Genetics and Heterogeneity

Genetic Predisposition to Kidney Cancers

Personalized Medicines for Kidney Cancers

Drugs in the Pipeline

Resistance to Therapy Among Kidney Cancers

Targeted Therapy

The Role of Neoadjuvant Tx

Sx Options – Ablative Techniques

Sx Options – Lymph Node

Sx Options – Cytoreductive Nephrectomy

TKIs – First-Line Therapy

TKIs – Second-Line Therapy

Biomarkers in RCC

The MET Pathway

Checkpoint Inhibitors

RENAL CELL CARCINOMA NEWS

Combining 2 predictors yielded better results than just using 1.

Papillary RCC Subtype Not Predictive of Survival, Study Finds

December 17, 2020

There are estimated to be 13 distinct hereditary renal cell carcinoma (RCC) syndromes, each of which

Can Measurements of Tumor Perfusion Predict Response to VEGFR-Targeted TKI Therapy in Metastatic RCC?

December 10, 2020

The condition appears to be associated with high hospitalization and death rates, researchers report

Kidney Cancer Stage Migrated Downward in Low-Income Patients After ACA

December 10, 2020

Bone with cancer

Bone Metastases in mRCC May Not Portend Worse Prognosis

December 10, 2020

Adjuvant treatment with sorafenib or sunitinib are no more effective than a placebo in preventing re

No Benefit to Modified Dosing of Lenvatinib-Everolimus in Advanced RCC

November 7, 2020

Next post in Renal Cell Carcinoma

There are estimated to be 13 distinct hereditary renal cell carcinoma (RCC) syndromes, each of which

Can Measurements of Tumor Perfusion Predict Response to VEGFR-Targeted TKI Therapy in Metastatic RCC?